Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer

Journal of Urology

Volumn 188, Issue 6, 2012, Pages 2190-2197

  Jilg, C A ^a   Rischke, H C ^a   Reske, S N ^b   Henne, K ^a   Grosu, A L ^a   Weber, W ^a   Drendel, V ^a   Schwardt, M ^a   Jandausch, A ^a   Schultze Seemann, W ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

lymph node excision; positron emission tomography and computed tomography; prostatic neoplasms; recurrence; salvage therapy

Indexed keywords

FLUORETHYLCHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LYMPH NODE DISSECTION; MALE; NODAL RECURRENCE OF PROSTATE CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE CANCER; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME;

AGED; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY;

EID: 84869084594     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.08.041     Document Type: Article

References (30)

1. M. Han, A.W. Partin, M. Zahurak Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer J Urol 169 2003 517
2. Wirth M, Weiβbach L and Alberti W: S3-Leitlinie Prostatakarzinom. Leitlinienprogramm Onkologie der AWMW, Deutschen Krebsgesellschaft eV und Deutschen Krebshilfe eV 2011; Version 2.0, 1. Aktualisisierung 09.2011.
3. C.S. Higano Side effects of androgen deprivation therapy: monitoring and minimizing toxicity Urology 61 2003 32
4. R.C. Benson Total androgen blockade: the United States experience Eur Urol 24 1993 72
5. E.D. Crawford A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer Urology 46 1995 899
6. A.M. Hovels, R.A. Heesakkers, E.M. Adang The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis Clin Radiol 63 2008 387
7. V. Scattoni, M. Picchio, N. Suardi Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy Eur Urol 52 2007 423
8. L. Rinnab, F.M. Mottaghy, N.M. Blumstein Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer BJU Int 100 2007 786
9. C.J. Ryan, E.P. Elkin, J. Cowan Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE Cancer 110 2007 81
10. S. Daneshmand, M.L. Quek, J.P. Stein Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results J Urol 172 2004 2252
11. C. von Bodman, G. Godoy, D.C. Chade Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy J Urol 184 2010 143
12. R. Schiavina, F. Manferrari, M. Garofalo The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer BJU Int 108 2011 1262
13. A. Briganti, J.R. Karnes, L.F. Da Pozzo Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy Eur Urol 55 2009 261
14. D. Dindo, N. Demartines, P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 240 2004 205
15. D.J. Hernandez, M.E. Nielsen, M. Han Contemporary evaluation of the D'Amico risk classification of prostate cancer Urology 70 2007 931
16. B.F. Chapin, S.E. Delacroix Jr, S.H. Culp Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma Eur Urol 60 2011 964
17. D. Elias, O. Glehen, M. Pocard A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix Ann Surg 251 2010 896
18. J.A. Karam, C.G. Wood The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy Hematol Oncol Clin North Am 25 2011 753
19. B.I. Rini, S.C. Campbell The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy J Urol 177 2007 1978
20. M. Oderda, S. Joniau, M. Spahn Debulking surgery in the setting of very high-risk prostate cancer scenarios BJU Int 110 2012 E192
21. G.K. Zagars, A. Pollack, A.C. von Eschenbach Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer Urology 58 2001 233
22. T. Daly, B.E. Hickey, M. Lehman Adjuvant radiotherapy following radical prostatectomy for prostate cancer Cochrane Database Syst Rev 12 2011 CD007234
23. B.A. Jereczek-Fossa, G. Beltramo, L. Fariselli Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer Int J Radiat Oncol Biol Phys 82 2012 889
24. A. Mattei, F.G. Fuechsel, N. Bhatta Dhar The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study Eur Urol 53 2008 118
25. G. Giovacchini, M. Picchio, E. Coradeschi Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy Eur J Nucl Med Mol Imaging 37 2010 301
26. L. Rinnab, J. Simon, R.E. Hautmann [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy World J Urol 27 2009 619
27. A.J. Breeuwsma, J. Pruim, A.C. van den Bergh Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using (11)C-choline positron emission tomography Int J Radiat Oncol Biol Phys 77 2010 160
28. P. Rigatti, N. Suardi, A. Briganti Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography Eur Urol 60 2011 935
29. D. Schilling, H.P. Schlemmer, P.H. Wagner Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer BJU Int 102 2008 446
30. A. Winter, J. Uphoff, R.P. Henke Complete PSA remission without adjuvant therapy after secondary lymph node surgery in selected patients with biochemical relapse after radical prostatectomy and pelvic lymph node dissection Adv Urol 2012 2012 609612